August 28, 2020
Calvin Scott & Company Inc. is recalling three lots of hydrochlorothiazide because the light-sensitive tablets were repackaged into transparent pouches, according to the August 26, 2020, US Food and Drug Administration (FDA) Enforcement Report.
The recall affects the following hydrochlorothiazide products, which were distributed by Calvin Scott & Company throughout the United States:
- hydrochlorothiazide 25-mg tablets manufactured by Accord Healthcare (NDC 16729-0183-17) from lot 19355 (Exp. 3/21);
- hydrochlorothiazide 25-mg orange tablets manufactured by Unichem Pharmaceuticals (NDC 29300-0128-10) from lot 19260H (Exp. 1/21); and
- hydrochlorothiazide 50-mg tablets, 14-count bags, manufactured by Accord Healthcare (NDC 16729-0184-17), from lots 18252 and 19033 (Exp. 10/20).
Calvin Scott & Company Inc. initiated the voluntary recalls July 27, 2020. On August 20, 2020, the FDA designated the recall Class II. Under Class II recalls, use of the product could cause temporary or medically reversible adverse health consequences, or a remote possibility of serious harm.
Hydrochlorothiazide is a prescription diuretic used to treat high blood pressure and fluid retention.